Overview

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

Status:
Recruiting
Trial end date:
2025-04-12
Target enrollment:
Participant gender:
Summary
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Phase:
Phase 1
Details
Lead Sponsor:
University of Chicago
Treatments:
Nivolumab
Pembrolizumab